BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering creating testing and delivering transformative medicines for patients suffering from genetic diseases. The company operates in the genetic medicine sector translating research from academic laboratories and medical institutions into product candidates. BridgeBio was founded in 2015 and has since created 19 Investigational New Drug applications and received FDA approval for three products. The company's approach leverages advances in genome sequencing molecular biology and longitudinal data to link genes to diseases and develop targeted therapies.

BridgeBio generates revenue through net product revenue license and services revenue and royalty revenue. Net product revenue comes from the commercial sale of Attruby in the United States following its FDA approval in November 2024. License and services revenue includes upfront payments milestone achievements and service revenue from collaboration agreements such as the Bayer License Agreement and the KKC Agreement. Royalty revenue is earned from net sales of Beyonttra by Bayer in the European Union and by Alexion in Japan following regulatory approvals in those regions.

The company operates through the following segments: Acoramidis for the treatment and primary prevention of ATTR-CM Infigratinib for achondroplasia and hypochondroplasia BBP-418 for LGMD2I/R9 Encaleret for ADH1 Other development programs Other research programs

• The Acoramidis segment focuses on developing and commercializing acoramidis for the treatment and primary prevention of transthyretin amyloid cardiomyopathy (ATTR-CM).

• The Infigratinib segment is dedicated to the development of infigratinib for achondroplasia and hypochondroplasia, which are skeletal dysplasia conditions.

• The BBP-418 segment targets limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) through the development of BBP-418 as a potential therapeutic option.

• The Encaleret segment works on encaleret for the treatment of autosomal dominant hypocalcemia type 1 (ADH1) by modulating calcium-sensing receptor activity.

• The Other development programs segment includes preclinical and clinical development activities for product candidates that have been designated but are not individually reported due to their early stage or smaller scale.

• The Other research programs segment encompasses early-stage discovery research and exploratory studies that precede the formal designation of a product candidate.

BridgeBio operates in the highly competitive biopharmaceutical industry focused on rare genetic diseases where it faces competition from other companies developing therapies for similar indications such as ATTR-CM achondroplasia and muscular dystrophies. The company's competitive advantages include its proprietary pipeline of genetic medicine candidates its ability to translate academic research into therapeutic candidates and its strategic partnerships with major pharmaceutical companies like Bayer and Alexion for commercialization and distribution in key global markets.

BridgeBio serves patients with genetic diseases including those with transthyretin amyloid cardiomyopathy achondroplasia hypochondroplasia limb-girdle muscular dystrophy and autosomal dominant hypocalcemia type 1. The company's commercial product Attruby is distributed to patients in the United States through healthcare providers and specialty pharmacies while its partnered products Beyonttra and infigratinib reach patients in Europe Japan and other regions through collaborations with Bayer and Alexion respectively.